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Abstract 
 
Development of nanocarriers for drug delivery has received considerable attention due to their 
potential in achieving targeted delivery to the diseased site while sparing the surrounding 
healthy tissue. Safe and efficient drug delivery has always been a challenge in medicine. During 
the last decade, a large amount of interest has been drawn on the fabrication of surfactant-based 
vesicles to improve drug delivery. Niosomes are self-assembled vesicular nano-carriers formed 
by hydration of non-ionic surfactant, cholesterol or other amphiphilic molecules that serve as 
a versatile drug delivery system with a variety of applications ranging from dermal delivery to 
brain-targeted delivery. A large number of research articles have been published reporting their 
fabrication methods and applications in pharmaceutical and cosmetic fields. Niosomes have 
the same advantages as liposomes, such as the ability to incorporate both hydrophilic and 
lipophilic compounds. Besides, niosomes can be fabricated with simple methods, require less 
production cost and are stable over an extended period, thus overcoming the major drawbacks 
of liposomes. This review provides a comprehensive summary of niosomal research to date, it 
provides a detailed overview of the formulation components, types of niosomes, effects of 
components on the formation of niosomes, fabrication and purification methods, physical 
characterization techniques of niosomes, recent applications in pharmaceutical field such as in 
oral, ocular, topical, pulmonary, parental and transmucosal drug delivery, and cosmetic 
applications.  Finally, limitations and the future outlook for this delivery system have also been 
discussed. 
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1. Introduction 
Conventional drug delivery systems face some significant challenges, such as unfavorable 
pharmacokinetics and distribution, which can lead to unwanted side effects (1). Drug 
degradation in blood circulation by the reticuloendothelial system and insufficient drug uptake 
at the target site can reduce drug efficacy (2). Nanocarriers have been extensively investigated 
in the past decades to overcome the challenges associated with conventional drug delivery 
systems, due to the following advantages: a) facilitate targeted drug delivery to the diseased 
site; b) enhance absorption as surface area increases and hence increase bioavailability; c) 
improve pharmacokinetics and biodistribution of therapeutic agents; d) increase retention in 
biological systems and prolong the efficacy of drugs (2,3). Numerous papers have been 
published regarding the development of different types of nanocarriers, such as polymeric 
nanoparticles, solid lipid nanoparticles, liposomes, micelles, dendrimers, carbon tubules, 
mesoporous silica and quantum dots. However, only a few of them have demonstrated 
significant clinical potential (2,4). The ultimate goals for designing an effective nano drug 
delivery system include formulation with biocompatible and biodegradable materials; 
achieving target delivery of therapeutics to the pathological site without affecting the 
surrounding healthy tissue or organs; no premature or burst release; ability to load a significant 
amount of drug in order to achieve the desired therapeutic effect; controlled release of drug 
over an extended period to reduce dose frequency and improve patient compliance (1). Among 
the different drug delivery systems, niosomal delivery systems can achieve majority of the 
goals listed above.   
Niosomes are formed by self-assembly of non-ionic surfactants. They are structurally similar 
to liposomes and were developed as an alternative delivery system to liposomes, as niosomes 
can overcome the problems associated with large-scale production, sterilization and physical 
stability (5,6). Also, the raw materials for niosomes are relatively cheaper and more readily 
available than phospholipids used for liposomes. Niosomes can be prepared as unilamellar or 
multilamellar vesicles following similar preparation methods as liposomes (7,8). They were 
first reported by researchers from L’Oréal (Clichy, France) for cosmetic applications in the 
1970s and 1980s. Since then, niosomes have been extensively investigated for multiple 
applications in different fields including pharmaceutical, cosmetic and food sciences, leading 
to a large number of publications and patents (2). Niosomes can enhance drug delivery across 
the skin barrier – stratum corneum (SC) (9,10). Some mechanisms have been proposed to 
explain their penetration-enhancing effects (2). Topical vaccine delivery using niosomes as 
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carriers have been reported in the literature, where the antigen remains intact in the aqueous 
core while the niosomal components enhance penetration across the skin and initiate an 
immunological response. Niosomes are also studied for the ocular delivery of therapeutics due 
to their low toxicity and penetration enhancing effects (11-13). In anti-cancer research, 
niosomes can achieve targeted delivery of anti-cancer agents and decrease toxicity to reduce 
side effects associated with these drugs (4,14). Proniosomes are of particular interest in the 
pulmonary delivery of aerosol drugs through nebulization devices, where drug loaded 
proniosomes can be deposited into the deep lung and achieve a better therapeutic response (15-
17).  
This up-to-date review of niosome drug delivery systems covers the elemental composition of 
niosomes, recent advances of new materials, functionalized ligands for targeted delivery, 
fabrication methods and different types of niosomes. Characterization studies, applications in 
various fields including pharmaceutical and cosmetic and comments on limitations and future 
directions of the niosomal system are also presented. 
 
2. Types of niosomes 
Various kinds of niosomes have been reported in the literature. These are classified into 
different groups according to their size or number of lamellar layers. Based on the size, there 
are small unilamellar vesicles (SUV) and large unilamellar vesicles. Based on the number of 
bilayers, there are multilamellar vesicles (MLV) and small unilamellar vesicles (SUV) (2). The 
size of niosomes is also a crucial factor that affects the choice of administration route. 
Submicron size vesicles are suitable for intravenous or transdermal applications, whereas those 
up to 10 microns are often used for intraperitoneal, intramuscular, nasal and oral administration 
(18). Small unilamellar vesicles (SUVs) are produced from multilamellar vesicles by methods 
such as sonication, extrusion under high pressure and high shear homogenization. The size of 
SUVs is around 10 to 100 nm (Fig. 5a). They are thermodynamically less stable compared with 
other types of niosomes and have poor drug loading capacity for hydrophilic drugs as well as 
a higher tendency to form aggregates (2,3). Large unilamellar vesicles (LUVs) comprise a 
single bilayer surrounding the aqueous core and are around 0.1 to 1 m in diameter (Fig. 5b). 
LUV niosomes have a large aqueous compartment, can be used for encapsulation of 
hydrophilic drug molecules (2). Multilamellar vesicles (MLV) comprises several bilayers 
surrounding the aqueous lipid compartments separately. The diameter of these vesicles ranges 
 7 
from 0.5 m to 10 m (Fig. 5c). MLVs can be easily prepared without complex techniques and 
are more stable compared to the other two types of niosomes under normal storage conditions. 
Also, they are favorable in the loading of lipophilic drugs due to the presence of multiple 
bilayer membranes (2,3). 
 
2.1 Types of specialized niosomes 
2.1.1 Proniosomes 
Proniosomes are produced by coating a thin layer of non-ionic surfactant on a water-soluble 
carrier (2,11,19). To make proniosomes, the water-soluble carriers need to be non-toxic, safe, 
free-flowing and have good water solubility to allow easy hydration. Maltodextrin, sorbitol, 
mannitol, glucose monohydrate, lactose monohydrate, and sucrose stearate have been used to 
prepare proniosomes (2,19). Proniosomes present in a dry powder form and have several 
advantages over the conventional niosomes such as better stability, less likely to form 
aggregates as well as reduced drug leakage (3). Proniosomes can be prepared by various 
methods such as slurry method, slow spray coating method and coacervation phase separation 
method. They exist in two forms, depending on the method of preparation, which are dry 
granular proniosomes and liquid crystalline proniosomes (17,18,20-22). 
2.1.2 Elastic niosomes 
Elastic niosomes are flexible niosomes, which can pass through pores that are smaller than 
their size without destroying their structure. The components of these vesicles are surfactants, 
cholesterol, water, and ethanol (Fig. 6b). They are commonly used in topical or transdermal 
drug delivery owing to their ability to pass through small pores and therefore improve 
penetration through the skin barrier. Manosroi and colleagues prepared elastic niosomes for 
transdermal delivery of diclofenac diethylammonium; the deformability index was around 14 
times higher than conventional niosomes (23). Another study carried out by the same group of 
researchers found that elastic niosomes prepared by addition of sodium cholate improved 
transdermal delivery of papain for scar treatment (24). 
2.1.3 Discomes 
Discomes are a large disc-like niosomes. In previous work by Uchegbu and co-workers, 
discomes were prepared using hexadecyl diglycerol ether, cholesterol and dicetyl phosphate by 
mechanical agitation and sonication (25). In the study, they found the size of discomes were 
large (11 to 60 m) and further increased in size after sonication. Discomes are also 
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thermoresponsive; their structure becomes less organized when the temperature increases 
above 37 C. Abdelkader et al. investigated discomes for ocular delivery of naltrexone for the 
treatment of diabetic keratopathy (26). 
2.1.4 Bola niosomes 
Bola niosomes are made of bola surfactants. This particular type of surfactants was found in 
the membrane of archaebacteria in the early 1980s. They have two hydrophilic heads that are 
connected by one or two lipophilic linkers. Zakharova (2010) has shown that bola surfactants 
have a strong assembling ability, which was demonstrated by their much higher surface tension 
and lower critical micelle concentration than the conventional surfactants; further research 
revealed their tolerability both in vitro and in vivo (27).  
2.1.5 Transfersomes 
Transfersomes are novel deformable vesicular carrier systems primarily composed of 
phospholipids, which self-assemble into a lipid bilayer in an aqueous environment and close to 
form a vesicle. A lipid bilayer softening component is added to increase lipid bilayer flexibility 
and permeability. This is known as an edge activator. An edge activator usually consists of a 
single chain surfactant of non-ionic nature that causes destabilization of the lipid bilayer, 
thereby increasing its fluidity and elasticity (Fig. 6c). Transfersomes comprise both 
hydrophobic and hydrophilic moieties and as a result can accommodate drug molecules with a 
wide range of solubilities. They can act as a carrier for low as well as high molecular weight 
drugs (28). 
2.1.6 Aspasomes 
Ascorbyl palmitate has been explored as bilayer forming material; it forms vesicles with 
cholesterol, ascorbyl palmitate and a negatively charged lipid (dicetyl phosphate). Aspasomes 
are prepared by film hydration method followed by sonication. They have been studied for the 
transdermal delivery of active ingredients, and it was found that aspasomes can enhance 
transdermal penetration across the skin barrier. Gopinath and co-workers developed 
azidothymidine (AZT) loaded aspasomes for topical application. Transdermal permeation of 
AZT loaded in aspasomes was much higher than AZT solution and ascorbyl palmitate aqueous 
dispersion. Although no study was conducted to determine the mechanism by which aspasome 
is enhancing the permeation of AZT, it is speculated that due to its lipophilicity it partitions 
into lipids of the skin and by its amphiphilic character alters the intercellular space and thus 
improve permeation. This study also revealed that the antioxidant potency of ascorbyl moiety 
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is retained after converting ascorbyl palmitate been into vesicles, aspasome rendered much 
better antioxidant activity compared with ascorbic acid. The antioxidant property and skin 
permeation enhancing property indicate a promising future for aspasome as a transdermal drug 
delivery system (29). 
 
3. Formulation components and their effects 
The components for niosomes include surfactants (generally non-ionic surfactants), cholesterol 
and charge inducing agents (3,30,31). Understanding the physicochemical properties of these 
formulation components as well as their effects on niosomes is essential for preparing niosomes 
with desired properties (32,33). Formulation components such as surfactants, cholesterol, 
charge inducing agents, the effect of hydrophilic-lipophilic balance (HLB) value, liquid gel 
transition temperature will be discussed in the following sections (2,3). 
 
3.1 Surfactants 
Surfactants are amphiphilic molecules, which comprise a lipophilic tail and a hydrophilic head. 
They are classified according to the charges on their hydrophilic head groups, which are 
cationic, anionic, amphoteric and non-ionic (Fig. 1) (1). The tail group of surfactants can be 
alkanes, fluorocarbons, aromatics or other non-polar groups. Non-ionic surfactants are the 
major components of niosomes due to their low toxicity and biocompatibility compared with 
the other types of surfactants. A variety of non-ionic surfactants have been commonly used in 
the preparation of niosomes. For example, derivatives of alkyl ethers, alkyl esters, and sorbitan 
fatty acid esters (1-3,34).  
Alkyl esters include sorbitan fatty acid esters (Span) (Fig. 2) and polyoxyethylene sorbitan fatty 
acid esters (Tween), these surfactants are non-toxic and non-irritating. Tween surfactants are 
derived from a reaction between polyoxyethylene and sorbitan fatty acid esters. They have 
higher HLB values compared with surfactants in the Span family (2). Brij surfactants are an 
example of alkyl ethers. Among the members of the Brij family is Brij 30 (Polyoxyethylene (4) 
lauryl ether) with a phase transition temperature less than 10 C and able to form large 
unilamellar with high drug loading (35). 
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Sucrose esters (SEs) are another group of non-ionic surfactants, they have a sugar substituent, 
sucrose, as the polar head group and fatty acids as non-polar groups (36). As sucrose contains 
eight hydroxyl groups, compounds ranging from sucrose monoesters to octaesters can be 
produced. These esters contain different fatty acids (stearic, palmitic, myristic and lauric acid) 
in different ratios (37). The type of fatty acid and the degree of esterification determines the 
hydrophilic lipophilic balance (HLB) value and the melting point of these materials. They have 
HLB values from 1 to 16, because of this variety, they are applied in many areas of 
pharmaceutical and cosmetical technology as emulsifiers, solubilizing agents, lubricants, 
penetration enhancers and pore forming agents (38,39). SEs have low toxicity, they are 
biocompatible, are less hemolytic and irritating than other surfactants, and finally, they have 
excellent biodegradability (40). SEs have drawn a worldwide interest as permeation enhancers 
of reduced irritation potentials; they are approved by Food and Agriculture Organization 
(FAO), World Health Organization (WHO), in Japan, USA and Europe, as food additives 
owing to their high safety and excellent properties. Sucrose stearate and sucrose palmitate are 
approved as inactive ingredients by the Food and Drug Administration (FDA) and listed in the 
Inactive Ingredients Database for oral dosage forms and sucrose distearate and sucrose 
polyesters are listed for administration by topical route (39). Most applications of SEs are found 
in transdermal drug delivery while they are also studied for oral administration of antigens and 
sucrose stearate-based proniosomes have been investigated for pulmonary delivery of 
cromolyn sodium (20). 
Bola and Gemini surfactants are the newer generations of surfactants that have been 
synthesized to produce niosomes with optimal properties (2). Gemini surfactants have a low 
critical micelle concentration and are non-toxic, non-irritating and non-hemolytic (2,10,41). 
Bola surfactants are of higher solubility and higher critical micelle concentration (1). Another 
new type of surfactant is tyloxapol, which is composed of ethylene oxide and formaldehyde 
and forms niosomes in water. It is a non-ionic biological surfactant of alkyl aryl polyether 
alcohol type that has been used in ophthalmic preparations and as a mucolytic agent for 
pulmonary diseases (2). Sucrose stearate-based proniosomes derived from niosomes have also 
been explored for pulmonary delivery of cromolyn sodium (20). 
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3.2 Additive agents 
Various additives have been used for niosome membrane among which the most common and 
important of these agents is cholesterol (Fig. 3) (25). Cholesterol interacts with surfactant by 
forming a hydrogen bond between its hydroxyl groups and the alkyl chain of surfactant 
molecules. It increases the transition temperature of vesicles and hence can improve stability 
by altering the fluidity of chains in bilayers. When present in sufficient concentration, it 
abolishes the gel to liquid phase transition endotherm of surfactant bilayers (12,42-46). 
Cholesterol also improves EE due to its membrane stabilizing effect, as it distributes between 
the bilayer, occupying otherwise void space and decreasing membrane fluidity, thus enhancing 
stability (3,5,47-49). On the other hand, increasing cholesterol above a certain point may inhibit 
the formation of the regular linear structure of the vesicular membrane, as it competes with the 
drug molecules for space and excludes them (44,50).  
Cholesterol influences other properties such as membrane rigidity, permeability, and ease of 
hydration (51-53). The fluidity of the niosomal membrane is one of the critical factors 
governing the release of drug molecules. The difference in release behavior is due to the 
variation in cholesterol content in different niosomes. The amount of cholesterol required in a 
particular formulation is dependent on the HLB value of the surfactants; when the value is 
greater than 6; cholesterol must be used to form niosomes. For Span niosomes, Span 60 and 80 
can form niosomes requiring little or no addition of cholesterol due to their low HLB values. 
Tween 60, with a higher HLB, needs more cholesterol to maintain membrane rigidity (8). 
Drug loading capacity can be influenced by cholesterol, the addition of cholesterols delays drug 
release by abolishing gel to liquid phase transition and improving drug loading hydrophilic 
drugs (20). On the other hand, for lipophilic drugs, decreasing the concentration of cholesterol 
in the formulation lead to an increase in EE as cholesterol disrupts the regular linear structure 
of the niosomal membrane, which does not allow more entrapment for lipophilic drugs (54-
56).  
Charge inducing agents also play an essential role in stabilizing bilayer membranes by 
imparting either a negative charge or positive charge to the surface of the niosomes, preventing 
aggregation by electrostatic repulsion (57). Negatively charged ionic compounds such as 
dicetyl phosphate (DCP) and positively charged compounds like stearyl amine (STR) or stearyl 
pyridinium chloride are commonly used charge inducing agents in the preparation of niosomes. 
Generally, these charged molecules are added to the formulation in an amount of 2.5 to 5 mol % 
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(17,25,58,59). However, increasing amount of the charge inducing agents beyond the limit will 
prevent the formation of niosomes (3). 
 
3.3 Critical packing parameter 
Nonionic surfactants are composed of both polar and non-polar parts. The formation of bilayer 
vesicles instead of micelles depends on the HLB of the surfactant, chemical structure of 
surfactants and the critical packing parameter (CPP) (Fig. 4) (2). CPP can be expressed by the 
following equation: 
CPP = V/a0lc 
Where V is hydrophobic group volume, a0 is the area of hydrophilic head group and lc is the 
critical hydrophobic group length. 
From the CPP value, the type of micellar structure formed can be ascertained.  A CPP of less 
than 0.5 suggests the formation of spherical micelles, whereas a CPP between 0.5 and 1 
suggests the formation of bilayer micelles. A CPP of greater than 1 suggests the formation of 
inverted micelles. A comparison between Tween surfactants confirmed the influence of the 
surface area of the polar head. Tween 21 and 20 have the same alkyl chain but different 
hydrophilic head groups, which influences the HLB value, the former being HLB 13.3 and the 
latter being HLB 16.7 (3).  
 
3.4 Hydrophilic-lipophilic balance (HLB) 
HLB is an empirical expression for the relationship of the hydrophilic and the hydrophobic 
groups of surfactants (2). Surfactants with a higher HLB value are more water-soluble than 
surfactants with a lower HLB (8,42-44). HLB value affects the size of the niosomes as well as 
EE of the active ingredient (35,60,61). It has been reported that surfactants with an HLB value 
between 4 and 8 can form niosomes, whereas surfactants with an HLB value of 6 or higher 
require the addition of cholesterol to form niosomes. Surfactants with an HLB outside of this 
range do not form niosomes (62,63). 
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3.5 Gel liquid transition temperature (Tc) 
Gel liquid transition temperature (Tc) of the surfactants is an essential factor that influences 
the formation of niosomes. It affects EE, membrane fluidity, membrane permeability, and 
stability. Tc and the length of the alkyl chain of non-ionic surfactants are correlated with each 
other. Shorter alkyl chains have a lower Tc, which leads to the formation of “leaky” niosomes. 
Surfactants with a higher Tc are more likely to be in an ordered gel form, reducing bilayer 
leaking compared with surfactants that have a lower phase transition temperature (19,43). Tc 
is dependent on the degree of the unsaturated alkyl chain. Lack of saturation in the alkyl chain 
lowers Tc and increases chain fluidity and membrane permeability. Studies have shown that 
niosomes formed by surfactants with lower Tc are more flexible than those formed with a 
higher Tc. The temperature of the hydration medium should be higher than the Tc of the 
surfactant, as this affects the formation of niosomes and could induce modifications in the 
bilayer (64-66). 
 
4. Methods of preparation 
There are multiple methods for preparing niosomes. These include the thin film hydration 
(hand shaking) method, ether injection method, reverse phase evaporation method, trans-
membrane pH gradient drug uptake process, emulsion method, lipid injection method, micelle 
solution and enzyme method, bubble method, microfludization method, the formation of 
niosomes from proniosomes and supercritical reverse phase evaporation method. Some new 
methods have been developed in the past decade; for example, the supercritical reverse phase 
evaporation method was described by Manosroi and colleagues using supercritical carbon 
dioxide fluid (60). Another microfluidization method was introduced recently, which is rapid 
and provides controlled mixing of surfactant cholesterol solution and an aqueous solution in 
microchannels (3). Also, proniosome methods have been proposed to overcome physical 
instability issues. Niosomes obtained as a dry powder provide easy unit dosing and can also be 
applied in pulmonary delivery (61). The advantages and disadvantages of the different 
preparation methods are summarised in Table 1. Niosomes prepared by different method yield 
difference sizes of vesicles. The methods of preparation are detailed below. 
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4.1 Thin film hydration (hand shaking) method 
The thin film hydration method is a simple technique (Fig. 7); however, it requires the use of 
organic solvents to dissolve surfactant and cholesterol. Surfactants and cholesterol are 
dissolved in a round-bottomed flask followed by evaporation of the organic solvent to form a 
thin film on the bottom of the flask. Addition of aqueous medium swells the film from the wall 
of the round bottom flask at a temperature above the transition temperature of the surfactant 
for a specified period with constant mild agitation to produce multilamellar vesicles, which are 
then treated to produce unilamellar vesicles (2,3,67,68). 
 
4.2 Ether injection method 
In this method, surfactant and drug are dissolved in diethyl ether and injected slowly to an 
aqueous phase, then heated above the boiling point of the organic solvent (Fig. 8). This method 
produces LUVs and can be further treated to reduce the size (3,46). 
 
4.3 Reverse phase evaporation method 
In this method, surfactants are dissolved in an organic solution of ether and chloroform, 
followed by addition of an aqueous drug solution (Fig. 9). The two immiscible phases are then 
homogenized, and organic solvents are removed under reduced pressure to form a niosome 
suspension. This method is considered ideal for preparation of hydroxychloroquine niosomes, 
due to high EE, large particles size with a small variation (73). The reverse phase method has 
been reported to encapsulate large hydrophilic macromolecules with relatively higher EE than 
other methods (69). 
 
4.4 Trans-membrane pH gradient drug uptake process  
In this method, surfactants and cholesterol are dissolved in an organic solvent. This solution is 
then evaporated under reduced pressure to obtain a thin film on the wall of the round bottom 
flask (Fig. 10). Hydration of this film is carried out with a citric acid solution at pH 4 by vortex 
mixing. The resultant vesicles then undergo a freeze and thaw process for three cycles and 
sonication. An aqueous drug solution is then added and vortexed. The pH of this solution is 
adjusted to 7 and heated at 60 C to produce multilamellar vesicles (70).  
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4.5 Emulsion method 
With the emulsion method, surfactant and cholesterol are dissolved in organic solvent and then 
added to an aqueous drug solution to form an oil in water emulsion (Fig. 11). The organic 
solvent is then evaporated to obtain niosomal suspension in an aqueous medium (2). 
 
4.6 Lipid injection method 
This method does not require the use of organic solvents. Surfactant and cholesterol are melted 
and then injected into a highly agitated heated aqueous phase containing dissolved drug 
molecules to form a niosomal suspension (Fig. 12) (2).  
 
4.7 Niosomes prepared using micelle solution and enzymes 
Niosomes can be prepared with a mixed micellar solution by the use of enzymes. For example, 
esterases break the ester links of polyethylene stearyl derivatives leading to the formation of 
breakdown products such as cholesterol and polyoxyethylene, which can form multilamellar 
niosomes with the addition of dicetyl phosphate and other lipids (Fig. 13) (1).  
 
4.8 The bubble method 
The bubble method is a single step technique that does not require the use of organic solvents. 
Surfactants and cholesterol are added to a buffer solution at 70C, the dispersion is mixed for 
fifteen seconds with a high shear homogenizer, and nitrogen gas is passed through this solution 
leading to the formation LUVs (Fig. 14) (71). 
 
4.9 Microfluidization 
This newly developed method produces smaller unilamellar vesicles with narrow size 
distribution. A solution of surfactants and drug is pumped through an interaction chamber 
under pressure at a rate of 100 ml/min. The solution is then passed through a cooling loop to 
remove the heat produced during microfluidization to form niosomes (Fig. 15) (2).  
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4.10 Proniosomal method 
Proniosomes are produced by coating a water-soluble carrier material with non-ionic 
surfactants, such as water-soluble materials including sucrose stearate, maltodextrin or 
mannitol. The water-soluble carriers are covered by a thin layer of surfactant and are rehydrated 
under agitation in hot aqueous media to form a niosomal suspension. Proniosomes are obtained 
as a dry powder, thus eliminating the physical instability issue of niosomes, such as aggregation, 
fusion, and leaking. Proniosomes made from this method are stable during storage and transport; 
the dry powder also allows easy unit dosing for patients (2,20,21). 
Proniosomes can also be obtained using the coacervation phase separation method (Fig. 16). A 
mixture of surfactant, cholesterol, drug and phosphatidylcholine are dissolved in absolute 
ethanol in a wide mouth glass tube. The open end of this tube is covered with a lid and warmed 
in a water bath at 70ºC for 5 minutes. An aqueous phase is then added and warmed on a water 
bath until a clear solution is observed. The mixture is allowed to cool down at room temperature 
until the dispersion is converted into a proniosomal gel (12). 
 
4.11 Supercritical reverse phase evaporation method 
This method involves supercritical fluid as described by Manosroi and colleagues (60). It does 
not require the use of organic solvent, which can be difficult to remove and toxic. This method 
can also be easily scaled up to produce a large number of niosomes. However, large unilamellar 
niosomes are obtained with a size between 100 to 500 nm. Sonication or extrusion method can 
be combined with this method to produce smaller niosomes (2,72).  
 
5. Niosome purification 
Purification of niosomes is an essential step, as complete encapsulation of drug molecules in 
niosomes is seldom possible regardless of optimization of the drug loading processes. The free 
drug must be removed to prevent the burst release of niosomes when applied in in vitro and in 
vivo experiments (67). Purification methods used to remove unentrapped drug molecules 
include dialysis, gel filtration, and centrifugation. The dialysis method is based on the diffusion 
of the solute through a semi-permeable membrane, which is frequently used by researchers to 
remove free drug. Niosomes are filled into a dialysis bag and then dialyzed against a saline 
solution. The concentration of the drug in the saline solution is determined by 
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spectrophotometry (2). Purification of niosomes from the unencapsulated drug can be carried 
out by gel filtration chromatography on Sephadex G75, G50 or G25, which allows efficient 
separation of free drug molecules (2,72). Centrifugation and ultracentrifugation have also been 
used to purify niosomes. These methods can be applied to a variety of solutes and more than 
90% recovery can be achieved without dilution of niosome preparation (62,74,75). 
 
6. Characterization studies 
The characterization of niosomes includes parameters such as size, distribution, zeta potential, 
morphology, EE, and in vitro release behavior. These are studied to determine the quality of 
the niosomes in formulation development and their applications in future clinical studies. These 
parameters have a direct impact on stability and in vivo performance (2,3).  They are 
summarized in Table 2 and discussed in more detail below. 
 
6.1 Niosome particle size and size distribution 
Particle size is a fundamental parameter in the characterization of niosomes as it provides 
information on physical properties and stability of the formulation (3). The size of niosomes 
can be measured by techniques such as dynamic light scattering (DLS) and microscopy. DLS 
is also known as photon correlation spectroscopy (2). This method is rapid and non-destructive, 
and only a small amount of sample is required. It can be used to measure particles in the size 
range of 3 to 3000 nm. This technique is based on the principle of random Brownian motion 
of small particles dispersed in a medium. A laser generated by the equipment irradiates the 
niosome suspension and the niosomes scatter light. This is detected at either a fixed or variable 
scattering angle, with the intensity of the fluctuations in scattered light from the collision of 
particles arising from random Brownian motion as a function of time. Smaller particles produce 
higher intensity fluctuations due to their higher diffusion coefficient, whereas larger particles 
move relatively slowly and cause a lower intensity of fluctuations. The polydispersity index 
(PDI) is an indication of the distribution of niosome size, with PDI value of less than 0.5 
indicating a monodispersed sample. The limitation of DLS is that it does not provide any 
information on the shape of the niosomes (1). Electronic microscopic techniques are also used 
to determine the size of niosomes, DLS and microscopic techniques are sometimes used in 
combination to produce more reliable results (3).  
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6.2 Morphology 
Microscopic techniques are used to study the morphology of niosomes. Electronic microscopic 
methods including transmission electronic microscopy (TEM), negative-staining transmission 
electronic microscopy (NS-TEM) and freeze-fracture transmission electronic microscopy (FF-
TEM) are used preferentially for liquid state samples, whereas scanning electron microscopy 
(SEM) is used for solid samples. Atomic force microscopy (AFM) and scanning tunneling 
microscopy (STM) were used by Binnig’s group in 1982 for characterization of micro- and 
nano-scale structures. STM is useful in determining the bilayer thickness of liposomes and 
niosomes due to its analytical ability in the vertical axis (2,23,76).    
  
6.3 Zeta potential 
The zeta potential, which is also known as surface charge, provides essential information in 
determining the physical stability of niosomes. The surface potential can be measured by laser 
Doppler anemometry and the magnitude of zeta potential provides an indication of the degree 
of electrostatic repulsion between two adjacent particles. Niosomes with a zeta potential higher 
than 30 mV or lower than 30 mV are considered to have acceptable stability (3,77,78). 
 
6.4 Bilayer characterization 
Niosomes are either present in a single layer (unilamellar) or multiple layers (multilamellar) 
(3). The number of lamellae can be determined by small angle X-ray scattering (SAXS), 
nuclear magnetic resonance spectroscopy (NMR) and AFM. The SAXS can be coupled with 
energy-dispersive X-ray diffraction (EDXD) to characterize the thickness of niosomal bilayer. 
The fluidity of the niosomal membrane allows membrane deformation without changing 
bilayer integrity and can be measured by the mobility of the fluorescent probe as a function of 
time and temperature. Microviscosity of niosomal membranes can be determined by 
fluorescent polarization to study the packing structure of the lipid bilayer (60). 
 
6.5 Niosome stability 
Stability of the vesicular system is an issue and concerns not only physical and chemical but 
also biological stability. This fundamental parameter is used to determine the potential in vivo 
and in vitro application of the niosomes (64). Stability is generally determined by monitoring 
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particle size and zeta potential over time, with variations in these two parameters indicating 
possible instability. Stability is often determined over three months in different conditions, such 
as 4C, 25C, 40C at 75% relative humidity, to assess the effect of temperature on stability 
(20,49,55,67,79). 
 
6.6 Entrapment efficiency (EE) 
EE is described as the number of drug molecules that have been successfully entrapped within 
the vesicles and in this case the niosomes, and can be expressed by the following equation: 
               EE = (Amount of drug entrapped ÷ Total amount of drug added) x 100% 
The amount of drug entrapped refers to the actual amount of drug molecules been successfully 
enclosed in the vesicles and the total amount of drug refers to the amount of drug used in 
preparation (2). The free drug molecules need to be separated from the entrapped drug by 
methods such as dialysis, filtration or centrifugation (86,87). The EE can be determined by 
spectrophotometry, or by gel electrophoresis followed by UV densitometry for genetic 
materials (88). Moreover, this parameter can also be determined using a fluorescence marker 
such as calcein to evaluate the number of marker molecules entrapped (80-82). 
 
6.7 In vitro drug release 
In vitro release behavior of the niosomes is a fundamental parameter, which can be affected by 
many factors such as drug concentration, hydration volume, and nature of the membrane. The 
release of drug molecules from niosomes is generally studied using a dialysis membrane. This 
is where purified niosomal suspension without free drug is filled into a dialysis bag, then tied 
at both ends and placed in a beaker of phosphate buffered saline (PBS) at a constant temperature 
at 37C and under magnetic agitation. Samples are taken at predetermined time intervals and 
replaced with the same amount of fresh medium. These samples are then analyzed using 
appropriate assays to determine the concentration of drug released over time (34,76,78). Franz 
diffusion cells have also been used to study the release behavior of niosomes. This is where the 
dialysis membrane is placed between the donor and receptor compartment of the apparatus; the 
niosomal suspension is filled into the donor compartment. The receptor compartment contains 
PBS at pH 7.4 and the whole system is maintained at 37C. Samples are collected from the 
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receptor compartment at defined time intervals and replaced with the same amount of release 
medium (22,25,83-85).  
 
7. Applications of niosomes in drug delivery 
Applications of niosomes can be found in areas such as drug delivery and cosmetics, they are 
suitable for the delivery of many pharmaceuticals and have been studied for various routes of 
administration including oral, topical, transdermal, ocular, intravenous, pulmonary and 
transmucosal; the design of the formulation is influenced by the route of administration of the 
niosomal formulation (56,57,69,84,89,90). 
 
7.1 Oral delivery 
Oral delivery is widely regarded as the most accessible and convenient route of drug 
administration, especially when repeated administration is required. However, there are several 
challenges to consider when formulating oral drugs, such as the acidic environment of the 
stomach, enzymatic degradation in the gastrointestinal tract, first pass metabolism, poor 
absorption and variable drug bioavailability. Niosomes have been explored to overcome these 
challenges by improving absorption and bioavailability (3,91,92). Examples of niosomes that 
have been developed for oral delivery are outlined in Table 3. 
The first application of niosomes in oral delivery was reported in 1985 by Azmin et al., who 
found that the niosomal formulation significantly improved the bioavailability of methotrexate 
(93). Niosomes modified with polysaccharide o-palmitoyl mannan have also been studied for 
oral genetic immunization of hepatitis B (69). Niosomes have been investigated for oral 
delivery of lipophilic drugs such as diacerein, which has limited bioavailability due to low 
solubility and belongs to Class II of the Biopharmaceutical Classification System (BCS). 
Researchers investigated sorbitan monolaurate and Poloxamer 184 based niosomes for oral 
delivery of diacerein and found improved in vitro dissolution profiles of the niosomal 
formulations compared with diacerein aqueous suspension (57). Paclitaxel (PCT) is an 
anticancer drug used to treat several types of cancers including ovarian, breast, lung, cervical 
and pancreatic cancer. Bayindir and co-workers have successfully encapsulated this drug in 
various niosomal formulations. Niosomes composed of Span 40, cholesterol and DCP showed 
a high EE and better stability of PCT against gastric enzymatic degradation than other 
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formulations prepared with Span 20, 60, Tween 20, 60 and Brij 76, 78, 72. PCT released from 
niosomes by a diffusion-controlled mechanism and the resulting sustained release could be 
beneficial for reducing the adverse effects associated with PCT (91). Tramadol HCl 
encapsulated niosomes have been investigated for extending the analgesic effect following oral 
administration. Tramadol has poor bioavailability due to first pass metabolism, with only 68% 
of the administered dose reaching the blood circulation following a single oral dose, and 
patients often experience adverse side effects such as sedation. In order to improve 
bioavailability and reduce side effects, an oral dosage form was developed using niosomes. 
Proniosome gel and solution were prepared with Span and Tween surfactants, then niosomes 
were formed by mixing the heated phosphate buffered saline to the gels or solution of tramadol 
proniosomes. Oral administration of tramadol loaded niosomes to mice showed extended 
analgesic effects compared to tramadol solution (94).  
 
7.2 Topical and transdermal delivery 
Topical drug delivery has several advantages, such as localized drug release at the site of action 
and reduced side effects by minimizing systemic absorption (9,10). In transdermal drug 
delivery, the active ingredients are delivered across the skin for systemic circulation, which has 
several advantages compared with other routes of administration. Transdermal delivery has 
higher bioavailability as first-pass hepatic metabolism can be avoided, is non-invasive as no 
needle is required, avoids acidic and enzymatic degradation in the gastrointestinal tract and 
eliminates potential drug-food interaction. However, use of the transdermal route is limited due 
to the poor penetration rate of drug molecules, with the primary barrier for drug absorption 
across the skin being the stratum corneum (SC) (97,98). Low molecular weight (≤500 Da), 
lipophilicity, and effectiveness at low dosage are the ideal characteristics of the drugs for 
transdermal delivery (40). However, many drugs do not possess ideal physicochemical 
properties; only a minimal number of drugs have been successfully formulated into transdermal 
preparations. Topical applications of niosomes have been widely reported due to their ability 
to enhance cutaneous drug delivery to the epidermis and dermis layer (24,76,99-102). Several 
mechanisms have been proposed to explain their penetration-enhancing effects. Firstly, 
adsorption and fusion of drug-loaded vesicles onto the surface of the skin leads to a high 
thermodynamic activity gradient of the drug at the surface of vesicles and SC, which acts as a 
driving force for the penetration of drugs across the SC (55,58,103-106). Secondly, disruption 
of the densely packed lipids that fill extracellular spaces of the SC, enhance the permeability 
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of drugs through structural modification of SC. Thirdly, the non-ionic surfactants play a crucial 
role in improving penetration by acting as penetration enhancers. Wherein vesicle bilayers 
enter the SC with subsequent modification of the intercellular lipids, which increases overall 
membrane fluidity (50,55,58,84,104,105,107-112). Lastly, niosomes cause an alteration in the 
SC properties through a reduction in the trans-epidermal water loss, thus leading to an increase 
in SC hydration with the loosening of its closely packed cellular structure (55,104).  
An important research contributes to the evaluation of niosomes as permeation enhancers for 
transdermal delivery was made in 2011. It aimed to evaluate if the increased hydrophilic drug 
permeation across the skin, which is always observed with vesicular systems, is dependent on 
the structural organization of niosomes, that are used to transport the active molecule, or it is 
only dependent on the dual nature of surfactant. The study was designed to examine the real 
role of surfactant molecule and the influence of its structural organization on the ex vivo 
permeation of a hydrophilic drug. The percutaneous permeation profiles of sulfadiazine sodium 
salt were obtained, according to the following experimental conditions: a drug-loaded niosome 
formulation, drug solubilized in a sub-micellar solution of surfactants, a drug aqueous solution 
after skin pretreatment with empty niosomes, a drug aqueous solution after skin pretreatment 
with the sub-micellar solution of surfactants. The results showed that the permeation of 
sulfadiazine was not increased after pretreatment with sub-micellar solutions of surfactants or 
direct treatment with a sub-micellar solution of surfactant containing the drug respect to the 
control. Only the direct treatment of the skin with loaded niosomes gave a relevant increase of 
the percutaneous permeation of the drug, confirming their role as permeation enhancers. It has 
been reported that the intercellular lipid barrier in the SC would be dramatically changed to be 
more permeable by treatment with non-ionic surfactants in the form of niosomes that act as 
penetration enhancers (113). The possible mechanisms of action of niosomes to enhance skin 
penetration are shown in Fig. 17a-e. 
Moreover, topical application of niosomes is limited by its liquid nature of the preparation; 
when applied they may leak from the application site. This challenge is overcome by 
incorporation gelling agents to niosomal dispersion, thereby forming a niosomal gel. Niosomal 
gels can provide a reservoir of drugs in SC for the sustained release, which leads to high 
accumulation of drugs in the dermis and epidermis. The gel can also promote the penetration 
of drug across the SC owing to the occlusion effects from the gel formation which can enhance 
skin hydration and subsequently increase the absorption and penetration of drug across the skin 
(24,40). The most recent development in vesicle design for transdermal delivery is the use of 
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elastic vesicles, which differ from conventional niosomes by their characteristic fluid 
membrane with high elasticity. This feature enables them to squeeze themselves through the 
intercellular regions of the SC under the influence of transdermal water gradient upon 
application on the skin surface (24,107). Ethanol used in the preparation of elastic niosomes is 
known as an efficient permeation enhancer, it can interact with the polar head group region of 
the lipid molecules, resulting in the reduction of the melting point of the SC lipid, thereby 
increasing lipid fluidity, and cell membrane permeability (10). Penetration can also be due to 
the adhesion of the vesicle to the skin surface followed by the destabilization and finally the 
fusion with the SC lipid matrix. Studies have demonstrated that elastic vesicles were often 
localized and accumulated in the channel like regions which are located within the intercellular 
lipid lamellae of the skin surface (24). Manosroi and co-workers developed novel elastic 
niosomes entrapped with the non-steroidal anti-inflammatory drug, diclofenac 
diethylammonium for topical application. Various formulation composing of 
dipalmitoylphosphatidylcholine, Tween 61, or Span 60 mixed with different molar ratios of 
cholesterol and ethanol at 0%–25% (v/v) were prepared. Elastic Tween 61 niosomes were 
selected due to their better stability. The deformability index values for elastic niosomes were 
significantly higher than for the conventional empty or loaded niosomes, indicating the higher 
flexibility of the elastic vesicles, especially when entrapped with the drug. Gels containing 
elastic niosomes demonstrated enhanced transdermal absorption through rat skin by exhibiting 
higher fluxes of diclofenac in the SC, viable epidermis and dermis and receiver chamber 
compared to commercial emulgel containing an equivalent amount of drug. Diclofenac 
entrapped in the elastic niosomes and incorporated in the gel also demonstrated good anti-
inflammatory effect in the rat ear edema assay (23). 
Drugs with different physicochemical properties have been investigated for topical and 
transdermal delivery include diacerein (53), itraconazole (114), tretinoin (115), salidroside 
(104) and finasteride are listed in Table 4 (116). An exciting area in dermal drug delivery is a 
topical vaccine, niosomes have been studied in this area for delivery of antigens. The topical 
vaccine has the advantages of safety and flexibility. The skin acts as a barrier to protect from 
foreign invaders; there are specialized cells of the immune system throughout the layers of the 
skin, e.g., Langerhans cells, dendritic cells, and epidermotropic lymphocytes. Hepatitis B 
infection remains a significant worldwide health problem. Vyas and co-workers investigated 
niosomes for a non-invasive topical genetic vaccine against hepatitis B virus (69,117). DNA 
encoding hepatitis B surface antigen (HBsAg) were loaded in niosomes composed of Span 85 
and cholesterol. The immune-stimulating activity was determined by measuring hepatitis B 
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surface antigen titer and cytokine levels following topical application of antigen-loaded 
niosomes in Balb/c mice. Results were compared with naked DNA and liposome encapsulated 
DNA applied topically, naked DNA and pure recombinant HBsAg administered 
intramuscularly. Topical niosomes elicited a similar serum antibody titer and endogenous 
cytokine levels when compared to intramuscularly injected recombinant antigens (107,117). 
Gupta et al. also studied the topical delivery of tetanus toxoid for non-invasive immunization 
using transfersomes, niosomes, and liposomes. The in vivo study found that transfersomes 
elicited a higher immune response in comparison to niosomes and liposomes due to its elastic 
bilayer, which allows transfersomes to deform and pass through the minute pores present in 
the skin (107,117). Niosomes have been studied to deliver antioxidant enzyme catalase (CAT) 
for wound healing. Researchers used biocompatible non-ionic sugar ester surfactants to deliver 
enzyme catalases. The mean diameter of the resulting niosomes was around 222-275 nm and 
the catalytic activity of enzymes was improved after encapsulation by a factor of 1.7-fold. 
Further, the niosomes were able to preserve the catalytic activity for 180 days when stored at 
4C. The in vivo studies showed a significant improvement of the prepared CAT niosomes on 
wound healing (118). A hybrid system of moxifloxacin-loaded niosomes incorporated into 
chitosan gel was studied for preventing burn infection by Sohrabi et al.  The optimized 
niosomal formulation showed 74% EE and approximately 50% of the drug released in 8 hours. 
The gel embedded niosomes showed pseudoplastic flow behavior and more sustained release 
compared with niosomes. Both of the formulations were found efficiency against common skin 
bacteria, while the hybrid formulation was more superior against Staphylococcus aureus (119). 
 
7.3 Ocular delivery 
Conventional ocular drug delivery preparations such as eye drops, ointments, and suspensions 
are unable to achieve high bioavailability due to physiological barriers in the eyes, such as the 
barrier properties of retinal pigment epithelium and the endothelium lining the inner side of the 
retinal blood vessels. Also, a significant amount of the dose is usually washed away into the 
nasolacrimal ducts (56). Studies have shown that niosomes can overcome some of these 
barriers and may be suitable carriers for ocular delivery. Firstly, the nano-sized niosomes can 
resist drainage by reflex tearing and blinking. Secondly, niosomes are better retained on the 
eye surface compared to other carriers (12). Zeng and co-workers have investigated hyaluronic 
acid (HA) coated niosomes. HA is a linear polymer composed of long chains of repeating 
disaccharide units of N-acetyl glucosamine and glucuronic acid has attracted more attention in 
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ocular delivery as it is a natural component of the vitreous body and aqueous humor of the eye. 
The mucoadhesive property of HA facilitates ocular contact time of the formulation and hence 
improves drug absorption and bioavailability. This study demonstrated that HA-coated 
niosomes were able to prolong pre-corneal retention, increase aqueous humor 
pharmacokinetics and bioavailability of tacrolimus (11). Chitosan-coated niosomes were 
studied by Zubairu and his team for trans-corneal delivery of gatifloxacin. Niosomes were 
prepared with Span 60 by the solvent injection method and coated with different concentrations 
of chitosan. Permeation studies showed that the chitosan coated niosomes increased 
transcorneal permeation of gatifloxacin by more than two-fold when compared with the drug 
solution. The uncoated niosomes showed longer retention, which was further enhanced in 
coated niosomes (77).  Abdelkader and co-workers investigated niosomes and discomes for 
delivery of naltrexone hydrochloride. They evaluated spreading, rheological properties and 
their ability to prevent autoxidation of naltrexone hydrochloride in aqueous solutions. The 
prepared niosomes showed better wetting and spreading abilities than aqueous drug solutions. 
Niosomes were also significantly more viscous than the aqueous drug solution. The lipid 
content, size, and composition of niosomes are the main factors affecting the viscosity of 
niosomal dispersions. The stability of naltrexone hydrochloride was evaluated by exposing it 
to artificial daylight illumination; the niosomal dispersion was able to protect the extensive 
degradation of naltrexone from photo-induced oxidation compared with free naltrexone 
solution (26). Recently, proniosome-derived niosomes were developed for topical ocular 
delivery of tacrolimus; these niosomes were prepared with poloxamer 188, lecithin and 
cholesterol. Proniosomes were reconstituted to form niosomes with ethanol and a small amount 
of water before use. In vitro permeation studies were performed on freshly excised rabbit 
cornea, and it was determined that the cumulative permeation amount of tacrolimus from 
niosomes and the drug retention in the cornea was significantly increased compared with the 
commercial ointment. An In vivo ocular irritation test in rat eyes showed no irritation and good 
biocompatibility with the cornea. In vivo anti-allograft rejection assessment was performed in 
a rat corneal xenotransplantation model. The results showed that treatment with 0.1% 
tacrolimus loaded niosomes delayed the occurrence of corneal allograft rejection and 
significantly prolonged the median survival time of corneal allograft to approximately of 
fourteen days as compared with those treated with 1% cyclosporine eye drops, plain niosomes 
or untreated. The investigated niosomes showed a potential for ocular delivery of tacrolimus 
(12). 
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Cationic lipids have been used with non-ionic surfactants to fabricate cationic niosomes for 
gene delivery, as cationic lipids form complexes by electrostatic interactions upon the addition 
of negatively charged genetic materials. Cationic lipids are considered as “helper” lipids and 
have a marked influence on both the physio-chemical and biological properties of niosome 
gene carriers. Mashal et al. investigated the retinal gene delivery enhancement by lycopene 
incorporated into cationic niosomes based on N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium chloride (DOTMA) and Tween 60. Niosomes were prepared by the 
reverse phase evaporation method and characterized for size, zeta potential, PDI and capacity 
to condense, release and protect the DNA against enzymatic degradation. The results showed 
the incorporation of a natural lipid – lycopene to the niosome formulation significantly 
increased transfection efficiency in human retinal pigment epithelial cells without 
compromising cell viability. In vivo administration to the rat retina showed the niosomes were 
able to transfect the outer segment of the retina and indicated their potential application in 
retinal gene delivery (56). Table 5 lists the uses of niosomes in ocular delivery.  
 
7.4 Pulmonary delivery 
Pulmonary drug delivery is preferred over the oral route when treating diseases such as lung 
infection, inflammatory diseases of the respiratory tract, or lung cancer, as drugs are directly 
administered to the site of action for either local or systemic treatment. The lung contains the 
equivalent of approximately 2400 kilometers of airways and 700 million alveoli, with an 
estimated surface area of around 50 to 75 square meters (18,124). This large surface area is 
ideal for drug absorption, and drug delivery devices such as inhalers and nebulizers have been 
used for decades to treat various lung diseases. However, there are some limitations, such as 
the low efficiency of the inhalation systems and uneven drug loading per inhalation from the 
inhaler. Various drugs have been studied for pulmonary delivery including steroids, anti-
tuberculosis drugs, antifungal drugs and antibacterial drugs (18,124-126). Table 6 lists the 
application of niosomes in pulmonary delivery. Proniosomes have been investigated for 
pulmonary delivery of beclomethasone dipropionate. This technique allows the preparation of 
drug in a powder form, which forms niosomes by hydration before administration to patients 
(18). Amphotericin B-loaded niosomes have been studied both in vitro and in vivo for treating 
leishmania and aspergillosis. Researchers found a significant reduction in fungal lung burden 
in a rat model of invasive pulmonary aspergillosis and significant suppression of Leishmania 
donovani liver parasite. These results indicate that amphotericin B loaded niosomal 
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formulations enhanced pulmonary delivery while reducing toxicity by minimizing systemic 
exposure (124).  
 
7.5 Parenteral delivery  
The parenteral route is the most common and efficient way to administer drugs with poor 
bioavailability and narrow therapeutic index (2). Parenteral administration has additional 
advantages, such as a reduction in fluctuation of the steady-state plasma drug level, and 
maximum utilization of medicine. On the other hand, drawbacks include reduced potential for 
dosage adjustments, retrieval of the drug is difficult in case of toxicity, and injections can lead 
to low patient compliance due to needle phobia (69). Some progress has been made using 
nanocarriers, which are capable of achieving targeted drug delivery and sustained release, to 
overcome the problems associated with conventional parenteral delivery formulations (3). 
Niosomal formulations have been reported for parenteral delivery of a variety of drugs (Table 
7). Mukherjee and colleagues compared liposomes and niosomes for parenteral delivery of 
acyclovir. This study aimed to determine whether drug-loaded nanocarriers could achieve 
sustained release to reduce dose-related systemic toxicity. The results indicated that niosomes 
are better carriers for acyclovir as they showed better stability and achieved sustained release 
when compared to liposomes (127). Nystatin is a potent antifungal drug for the treatment of 
fungal infections on the skin and oral cavity. One study encapsulated nystatin in niosomes to 
obtain a safe and effective formulation for parenteral administration for patients with 
neutropenia. Niosomes were prepared with Span 40, Span 60, cholesterol, and positive and 
negative charge inducing agents. Neutral and positively charged niosomes showed the highest 
EE, but in vitro release studies showed that both types of niosomes had sustained release profile. 
In vivo studies demonstrated that nystatin loaded niosomes showed less nephrotoxicity, 
hepatotoxicity and pronounced efficacy in the elimination of fungal burden in experimental 
animals infected with Candida albicans compared with those treated with a drug solution 
injected intraperitoneally (128).  
Mullaicharam et al. investigated lung accumulation of rifampicin loaded niosomes following 
intravenous infusion in rats. Niosomes were prepared with Span 20, 40, 60 and 80 by thin film 
hydration method. The in vivo organ distribution pattern following intravenous injection was 
studied in albino rats to determine the potential of the delivery system for the site targeted 
delivery of rifampicin. A significant difference in the total drug concentration in the lung, liver, 
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kidneys and blood serum was found between the rifampicin loaded niosomes and free 
rifampicin solution (80). Pardakhty and co-workers prepared positively charged niosomal 
formulations containing sorbitan esters, cholesterol and cetyl trimethyl ammonium bromide by 
film hydration method for entrapment of autoclaved Leishmania major (ALM). Niosomes 
containing ALM and free ALM were subcutaneously injected to balb/c mice. Results showed 
that the ALM loaded niosomes had a moderate effect in the prevention of cutaneous 
leishmaniasis and can successfully delay the development of papules in studied animals (129). 
The parenteral route is commonly used in chemotherapy to administer antineoplastic drugs. 
Using niosomes as carriers could achieve selective drug delivery to the tumor site, hence reduce 
toxicity and side effects. For instance, intravenous administration of hydroxycamptothecin 
loaded niosomes to sarcoma 180 ascites tumor-bearing mice lead to a total regression of tumor 
and a slower elimination from the systemic circulation (130). pH-sensitive niosomes are also 
studied for parenteral delivery of anticancer drugs. The tumor targeting effect of these 
niosomes loaded with 5-fluorouracil was demonstrated by accumulation at the tumor site of 
mice transplanted with tumor cells (131). Cisplatin niosomes (CP-NMs) were prepared with 
Span 40 and cholesterol, and their anticancer efficacy was investigated in vivo using rabbits 
bearing VX2 sarcoma. Rabbits were locally injected with either CP-NMs or a drug solution, a 
significant inhibition of tumor growth with much lower mortality, as well as inhibition of tumor 
metastasis to liver and inguinal lymph nodes were observed in the group treated with CP-NMs. 
The results indicated that CP-NMs could be developed as an effective anticancer preparation 
with low toxicity (132). Recently, Shaker investigated tamoxifen citrate (TMC) loaded 
niosomes for localized cancer therapy through in vitro cancer cytotoxicity as well as in vivo 
solid anti-tumor efficacy. Niosomal formulations were prepared with Span 40, 60, 80, Tween 
20 and cholesterol at different molar ratios using the thin film hydration method. Niosomes 
prepared with Span 60 were spherical with an EE up to 92.3%. Sustained release of TMC was 
observed from the optimized niosomal formulation and in vitro studies showed enhanced 
cellular uptake and greater cytotoxicity. In vivo studies were performed using the Ehrlich 
carcinoma mice model and a reduced tumor volume of niosomal TMC was observed when 
compared to the free TMC solution (43). 
 
7.6 Transmucosal drug delivery 
Bioadhesion has been widely studied in the development of pharmaceutics to improve local 
and systemic absorption. Transmucosal drug delivery has gained impressive momentum in the 
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past decade, especially with nano drug delivery systems (133-135). Transmucosal drug 
delivery routes include ocular, nasal, oromucosal (buccal, sublingual and gingival), pulmonary, 
gastrointestinal and vaginal sites. When considering the potential of these sites for drug 
administration, each has distinct features. When designing a suitable drug delivery system, 
these features need to be considered. Niosomes are a versatile drug delivery system and due to 
their advantages, they have been studied for transmucosal delivery of various compounds 
through the oral, nasal and vaginal mucosa (Table 8). Benzocaine proniosomal gel formulations 
were prepared by El-Alim and co-workers using Span 80, Span 80, Span 85, and combinations 
of the three to achieve effective buccal delivery of benzocaine for local anesthesia. EE was 
found to improve with increasing ratio of Span 80 or Span 85, and in vitro drug release studies 
showed an initial burst release followed by a slower release. Formulations prepared with Span 
80 and 85 showed better rate and extent of benzocaine permeation when examined using 
chicken pouch as a model mucosal membrane. Physical stability studies showed more than 90% 
of drug remaining after storage for one month at 4-8C. Benzocaine loaded proniosomes 
improved permeation through the mucosal membrane and could be used for managing mucosal 
pain (133). There is increasing interest in the establishment of protective mucosal immunity, 
which could be achieved by vaccination via mucosal routes. Oral immunization is the safest 
and most convenient means to induce mucosal immunity (3). Orally delivered antigens are 
taken up through the specialized epithelial cells. The selected antigen is then transported into 
the regional lymphoid tissue, stimulating specific B lymphocytes in the germinal canter (136). 
Most antigens are poorly immunogenic when processed through the mucosal surface, 
stimulating only weak or no immunoglobulin response (137). The effective mucosal response 
can be elicited with the use of adjuvants or novel carrier systems. Polysaccharide capped 
particles have several advantages such as increased stability against enzymatic attack and 
improved biochemical stability. Katare and co-workers developed polysaccharide-capped 
niosomes for oral mucosal vaccination of tetanus toxoid. In this study, niosomes were prepared 
by the reverse phase evaporation method using Span 60, Tween 20, stearylamine, and 
cholesterol, before being coated with pullulan derivative (O-palmitoyl pullan). Serum 
immunoglobulin level was measured to assess the immune stimulating effect of the niosomes 
following oral administration. The coated niosomes were able to produce an immune response 
equivalent to injected tetanus toxoid (96).  
Transmucosal delivery through the nasal mucosa has been studied in order to bypass the blood-
brain barrier for brain delivery. The use of this route will eliminate first pass metabolism, 
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reduce side effects as a result of systemic circulation, and improve bioavailability. Niosomes 
that are less than 300 nm can cross the blood-brain barrier; as niosomes can carry both 
hydrophilic and hydrophilic compounds, they have been investigated for delivery of various 
active agents. The study conducted by Abdelrahman et al. formulated elastic niosomes known 
as spanlastics for brain delivery of risperidone. These are sorbitan-based nano particles, 
modified from conventional niosomes by incorporating an edge activator to impart flexibility 
to their membranes. The spanlastics were prepared with Span 60 and polyvinyl alcohol using 
the ethanol injection method.  Ex vivo permeation was conducted using sheep nasal membrane 
to investigate the effect of spanlastics to improve permeation. The optimized formulation 
showed significantly higher transnasal permeation and better distribution to the brain when 
compared with the drug solution. The improvement in brain targeting and percentage of drug 
transported through the olfactory pathway suggests this may be a promising system that can 
effectively carry drug from nose to brain (134).  
Chattaraj and colleagues investigated the nasal mucosal delivery of influenza antigens using 
niosomes. The dehydration-rehydration method was used to encapsulate vital influenza antigen, 
and the influence of the different proportion of surfactant, cholesterol and dicetyl phosphate on 
morphology, particle size, EE and in vitro release was studied. Stability of the antigen 
encapsulated in the vesicles was confirmed by using SDS-polyacrylamide gel electrophoresis 
and immunoblotting. Span 60 based niosomes were found to be best for antigen encapsulation 
(135). Zidan and co-workers investigated the vaginal delivery of an anti-AIDS niosomal gel. 
This study aimed to improve mucoadhesion and skin permeation. According to the (BCS), 
tenofovir is a drug substance with high solubility and low permeability (BCS Class 3). Its poor 
permeation limits its antiretroviral potency. Chitosan was used as a mucoadhesive agent in the 
formulation, and a full factorial design was used to optimize the transmucosal delivery and 
mucoadhesion characteristics. The niosomal gels were characterized by investigating their 
vesicular size, shape and surface charge, drug EE, in vitro release and skin permeation. An ex 
vivo study using porcine vaginal tissue was also assessed. It was found that the mucoadhesion 
percentage was increased by five-fold and was further improved by decreasing the niosomal 
vesicular size and by increasing the surface charge. The formulation did not affect the viability 
of Lactobacillus crispatus, a common commensal bacterium found in the vagina, suggesting 
the niosomal gel could be promising for vaginal delivery of antiviral drugs (138). Another 
study investigated cationic niosomes for intravaginal administration of metformin 
hydrochloride for the treatment of polycystic ovary syndrome (PCOS). In this study, the 
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niosomes were loaded with thermosensitive gel to improve mucoadhesion on the vaginal 
mucosa. Oral administration of metformin is limited by impaired bioavailability and frequent 
dosing for patients with PCOS is required to maintain therapeutic effects, which can ultimately 
influence patient compliance and treatment outcomes. In this study, metformin loaded 
unmodified and cationic small unilamellar niosomes were incorporated with thermosensitive 
gel through the vaginal route. Both types of niosomes were prepared by the reverse phase 
evaporation method and characterized to determine gelation time, gelling temperature, 
viscosity, mucoadhesiveness, and drug release. In vivo studies were conducted on PCOS rats, 
under a scheduled dosage regimen with oral metformin solution or intravaginal gels loaded 
with either small unilamellar niosomes or cationic small unilamellar niosomes. Results showed 
that the gels offered similar advantages as compared to oral metformin solution in the treatment 
of PCOS at lower dose-dosage regimen with negligible side effects. However, no significant 
difference was detected between the gels (28).  
A clinical trial was conducted on niosomal propolis as an oromucoadhesive film for the 
treatment of recurrent aphthous ulceration (RAU). The films were prepared by loading propolis 
in niosomal vesicles and then incorporated into oromucoadhesive films. A total of 24 patients 
suffering from RAU were divided equally into medicated and placebo groups and participated 
in this study to examine the onset of ulcer size duration, complete healing and pain relief for 
two weeks. Results revealed the duration of film adherence lasted from 2 to 4 hours in the two 
groups. The onset of ulcer size reduction in the medicated group was observed within the 
second and third day, pain relief lasted for more than 4 to 5 hours after application, and five 
patients reported complete healing within the five days of treatment, and seven patients had 
complete ulcer healing within the period from day 5 to day 10 of treatment. On the other hand, 
no patients in the placebo group reported healing of ulcer during the first five days of treatment, 
and eight patients had complete ulcer healing from day 10 to day 15 of the treatment (139). 
Priprem and co-workers conducted a clinical trial to investigate the pharmacokinetics of a 
melatonin niosomal oral gel in human subjects. Melatonin loaded niosomal oral gel has been 
formulated in order to overcome the problems associated with poor drug absorption and 
stability. This randomized, double-blind, three phase crossover design recruited 14 male 
volunteers. Melatonin oral gel was applied topically on labial mucosa at doses of 2.5, 5 and 10 
mg with seven days washout for each period. The pharmacokinetic parameters that were 
determined included the maximum plasma concentration (Cmax), area under the curve (AUC), 
time to peak concentration (Tmax) and elimination half-life (t1/2). Possible side effects including 
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nausea, vomiting, headache, and irritability were also evaluated in the study. Results showed 
that the three different doses of melatonin niosomal oral gel provided dose-proportional 
pharmacokinetic profiles, extended the absorption process and improved plasma concentration, 
time to maximum plasma concentration and half-life compared to conventional immediate 
release oral dosage forms (140).  
 
7.7 Cosmetic applications of niosomes  
Niosomes were first developed and patented by a cosmetic company L’Oréal (Clichy, France) 
in 1975, and products were launched under the trade name of Lancôme (Paris, France) in 1987. 
Since then, a wide range of pharmaceutical applications and a variety of cosmetic products 
were developed and marketed with various functions, such as anti-wrinkle, skin whitening, 
moisturizing and sunscreen (141,142). Some examples of commercialized cosmetic products 
containing bioactive compounds loaded in niosomes are listed in Table 9.  
Niosomes have been widely investigated as a carrier system for cosmetic actives because of 
their advantages such as improved stability of entrapped active ingredients, enhanced skin 
penetration, bioavailability, improved surface adhesion and sustained release properties (143). 
The usefulness of niosomes in cosmetic formulations has been evaluated with respect to 
conventional formulations such as emulsions. Niosomes showed lower toxicity, allowing 
controlled delivery of the loaded active ingredients that exhibit useful properties for skin 
moisturizing and tanning products (144). Some bioactive ingredients extracted from plant 
materials are of particular interest in cosmetic research; these compounds possess beneficial 
effects such as antioxidant and anti-aging. A large number of plant-based bioactive compounds 
have been investigated using niosomes to improve their effects on the skin. Pando and co-
workers prepared liposomes and niosomes for topical delivery of resveratrol; olein was used 
as a penetration enhancer for both vesicles. Negatively charged vesicles with a mean size 
around 200 nm were obtained. Results showed high accumulation and low transdermal delivery 
of resveratrol for both vesicles when compared with the control; this phenomenon was more 
significant for niosomes, which showed better behavior for cutaneous delivery of resveratrol 
(145). Curcuminoids found in turmeric are major bioactive substances that possess antioxidant, 
anti-inflammatory and anti-cancer properties. These were encapsulated in niosomes for 
enhancement of skin permeation and an EE of 83% was obtained. An in vitro penetration study 
showed that niosomes significantly enhanced permeation of curcuminoids when compared 
with the control solution. The fluxes of curcumin, desmethoxycurcumin, and bis-
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desmethoxycurcumin were 1.117, 0.273 and 0.057, consistent with the lipophilicity of the three 
compounds, showing improved properties of curcuminoids by encapsulation in niosomes for 
skin delivery (146). Elastic and non-elastic niosomes loaded with gallic acid isolated from 
Terminalla chebula galls were investigated for transdermal absorption. Both niosomes showed 
negative zeta potential in the size range of 200 to 400 nm. The percentages of gallic acid in 
non-elastic niosomes were higher than in elastic niosomes. An in vivo penetration study showed 
elastic niosomes exhibited higher percentages of gallic acid through rate skin than non-elastic 
niosomes. The authors concluded that niosomes, especially elastic niosomes, were able to 
enhance chemical stability and skin penetration of gallic acid and could be useful carriers for 
skin anti-aging molecules (65). Niosomes loaded with caffeine for treatment of cellulite were 
formulated and evaluated by Mahmoud and co-workers for the treatment of cellulite. Histology 
revealed a significantly greater reduction in the size and thickness of the fatty layer of rat skin 
for the niosomal gel containing system, when compared to the commercial product Cellu 
Destock®. Further, a higher plasma concentration of caffeine was observed in the niosomal 
group, indicating that incorporation of caffeine into a niosomal system improved penetration 
through the skin and into the underlying fatty layer. This presents a promising approach for the 
formulation of a transdermal anti-cellulite product of caffeine in a niosomal gel system with 
improved transdermal bioavailability (147). Similarly, a transdermal gel prepared with elastic 
niosomes loaded with papain has been investigated in comparison with polymeric 
nanoparticles. Elastic niosomes demonstrated enhanced penetration of papain in rat skin, better 
transdermal absorption, and reduced scar formation when compared with polymeric 
nanoparticles (24).  Ellagic acid (EA) is a potent antioxidant. However, its application is limited 
by poor solubility and low permeability. EA niosomes prepared with Span 60 and Tween 60 
have been investigated in transdermal delivery. The results showed that the niosomal 
formulation could enhance skin penetration when compared to the EA solution, by improving 
its distribution in the human epidermis and dermis layer (120).  
 
7.8. Targeted drug delivery 
Targeted drug delivery by niosomal systems can be achieved by two approaches. Firstly, 
passive targeting of the reticuloendothelial system (RES), which is a part of the immune system 
that comprises phagocytic cells located in reticular connective tissue. The circulating serum 
factor, opsonin, marks the niosomes for clearance by macrophages (114). Agrati et al. showed 
that Tween 20 niosomes have intrinsic selectivity to phagocytic cells such as macrophages. For 
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this reason, niosomes can be used to treat infectious diseases in which the infecting organism 
resides in the RES. Secondly, niosomes can be conjugated with functionalized ligands to 
achieve targeting to specific organs or tissues (148). Bragagni and colleagues developed a 
brain-targeted delivery system loaded with doxorubicin for cancer. Niosomes prepared in this 
work were conjugated with a glucose derivative N-palmitoyl glucosamine ligand. Intravenous 
injection of this formulation to rats resulted in reduced drug accumulation of doxorubicin in 
other organs such as the heart, longer blood circulation time and an increased brain 
concentration with respect to the commercial formulation of the drug (149). The same 
functionalized niosomes were also studied for brain-targeted delivery for dynorphin-B. In vivo 
studies in mice by intravenous injection of the niosomal formulation showed a significantly 
higher antinociceptive effect compared with the drug solution at the same concentration (47). 
Another study explored the possibility of a combination of the PEGylated niosomes and active 
targeting function of transferrin by transferrin receptor-mediated endocytosis to promote drug 
delivery to solid tumor following intravenous injection with hydroxycamptothecin as the model 
drug. Niosomes were prepared by thin film hydration method, and periodate-oxidated 
transferrin was coupled to polyethylene glycol to produce the active targeting niosomes (Tf-
PEG-NS). The strongest cytotoxicity to three carcinomatous cell lines in vitro was 
demonstrated by Tf-PEG-NS when compared with drug solution, non-stealth niosomes, 
PEGylated niosomes, Tf-PEG-NS showed the most powerful anti-tumor activity with the 
inhibition rate of 71% against S180 tumor in mice, suggesting transferrin modified PEGylated 
niosomes could be promising for delivering anti-tumor drugs to tumor (150). 
 
8. Delivery of bioactive compounds  
Nanocarriers such as liposomes, solid lipid nanoparticles and niosomes have been investigated 
to deliver vitamins, plant constituents and other bioactive compounds. Modifying the 
pharmacokinetics of phytochemicals may enhance or modulate delivery to the target site and 
achieve better effect upon administration. Various natural products have been loaded into 
niosomes, such as ginkgo biloba extract, curcumin, rutin, and rice bran extract. Table 10 lists 
the application of niosomes in bioactive delivery (24,72,109,151-154). These formulations 
were prepared for various routes of administration, including dermal, oral, subcutaneous and 
rectal. Ginkgo biloba extract (GbE) loaded niosomes showed improved in vivo distribution 
after oral administration when compared to conventional GbE tablets (151). Silymarin is an 
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active extract from milk thistle, a complex of flavonolignans and polyphenols that has poor 
bioavailability. A niosomal formulation was developed and in vivo studies performed in albino 
rats showed a significant reduction in both transaminase level as well as in serum alkaline 
phosphatase level after subcutaneous injection when compared with silymarin suspension 
(154). Moreover, the biochemical markers assessed showed an excellent antioxidant activity 
of the niosomal formulation (155).  
 
9. Limitations and perspectives 
Niosomes have attracted a great deal of attention in controlled drug delivery because of many 
advantages, such as biodegradable, biocompatible, chemical stability, able to improve the 
therapeutic performance of drug molecules by modulating drug release. Despite numerous 
studies and with respect to the fact that niosomes have a long way to become a clinical reality, 
there are still multiple and serious challenges regarding the niosomes. The major obstacle that 
hinders the utilization of niosomes as potential drug delivery system is sterilization. Heat 
sterilization such as dry heat and steam sterilization are inappropriate and destructive for lipid 
or surfactant-based formulations with a gel liquid transition temperature lower than the 
temperature used in the sterilization process, as heat can cause extensive drug leakage from the 
vesicles due to the destruction of the bilayer membranes (3). Similarly, membrane filtration is 
not suitable for niosomes that are larger than the pore size (0.22 µm) of the membrane filters. 
Preparation under aseptic conditions could be a possible solution, as well as methods that 
generate minimal heat such as gamma irradiation. Niosomes can be prepared under aseptic 
conditions by filtering all organic solvent, buffer, surfactant solution, and drug solution through 
anti-bacterial filters, autoclaving glassware and working under aseptic conditions in a laminar 
fume hood that produces sterile airflow. The gamma sterilization process uses Cobalt 60 
radiation to kill microorganisms, which yields quick turnaround time and can easily penetrate 
packaging and products as a minimal amount of heat is generated. Many marketed 
pharmaceutical products such as eye ointments, drops and injectable preparations are gamma 
radiation sterilized (157). This method could potentially be applied onto niosomes, and hence 
the effect of gamma irradiation on the physical and chemical stability of niosomes can be 
studied in future work. 
Surfactants as building components of niosomes have the most critical role in the formation 
and properties of these carriers, and potential toxicity of surfactants is another limitation. 
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Segregation of surfactants may cause some degree of toxicity; there is not enough research 
about the toxicity of niosomes as minimal studies have been conducted on this topic. Hofland 
et al. evaluated the inhibition of human keratinocyte cell proliferation by different niosomal 
formulations, in particular, the effect of surfactants and concentration of cholesterol. The 
surfactants were of different hydrocarbon chain length and polyoxyethylene chain length. 
Ether- and ester-type surfactants were also investigated. The study reported that both the 
hydrocarbon chain and the polyoxyethylene chain length had minor effects on cell proliferation. 
However, the bond by which the alkyl chain was linked to the polyoxyethylene head group 
significantly influenced cell proliferation.  Ester-type surfactants were less toxic compared to 
the ether-type surfactants, which was attributed to enzymatic degradation of the ester bond. 
Cholesterol in the bilayers has not been found to affect cell proliferation  (158,159). Niosomes 
prepared using Bola-surfactants showed safety and tolerability both in vitro on human 
keratinocytes up to incubation of 72 hours and on human volunteers, with no skin erythema 
observed when topically treated with drug-free Bola niosomes (160). Recently, the ocular 
toxicity of niosomes has been investigated by measuring conjunctival and corneal irritation 
potential of Span 60 niosomes and surface modified Span 60 niosomes using hen’s egg 
chorioallantoic membranes and excised bovine corneal opacity and permeability models. The 
study showed minimal ocular irritations and suggesting good ocular tolerability for niosomes 
(26). Currently, data related to the cytotoxicity of niosome as well as surfactant molecules have 
been reported by many papers; however, there are no specific studies aimed to investigate 
toxicity after administration in animal models, particularly in long term studies. Filling the gap 
in research on long term tolerability of using surfactant-based systems would be fundamental 
before reaching clinical reality.  
From the vast literature on niosomes, it appears that not much attention was focused on 
exploring the possibility of using amphiphilic molecules are biologically active or can serve as 
targetable ligands, into bilayer vesicles. However, very few materials with dual qualities such 
as amphiphilicity and biological activity may be available. Therefore, it would be useful to 
synthesize such amphiphilic materials which can be converted into bilayer vesicles for drug 
delivery. Uchegbu and co-works were working on these compounds; for example, they 
synthesized palmitoyl muramic acid and N-palmitoyl glucosamine and prepared niosomes with 
these materials (161). 1-O-Alkyl glycerols isolated from shark liver oil have several biological 
activities, including macrophage activation and natural killer cell activation. They also have a 
prominent effect on blood barrier permeability and studies have shown that they markedly 
improve brain uptake of anti-cancer agents (162). Due to their surface-active properties, 
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Gopinath and his group have converted them into bilayer vesicles called algosomes. These 
vesicles are spherical and are capable of encapsulating drugs in the aqueous regions of the 
bilayer. However, they are osmotically sensitive, vulnerable to electrolytic destabilization and 
are stable for only a few days. Later, the same group developed ascorbyl palmitate vesicles 
(aspasomes) using ascorbyl palmitate. Several eater derivatives of ascorbic acid were 
synthesized to transfer the peculiar antioxidant properties of ascorbic acid in lipophilic media 
and to improve its stability, all of them retained the antioxidant property of the ascorbyl moiety 
and are amphiphilic. Ascorbyl palmitate is one of the derivatives, more stable than ascorbic 
acid and its lipophilic character is beneficial for skin penetration. Aspasomes prepared with 
this compound showed better antioxidant property when compared to ascorbic acid, and 
enhanced penetration of across the rat skin (29). The antioxidant property and skin permeation 
enhancing properties of aspasomes indicate a promising future for application as transdermal 
drug delivery systems in disorders implicate with reactive oxygen species. Thus, vesicles with 
biological activity or with a targeting function in addition to carrier properties will have an 
added advantage to increase the efficiency of niosomes, which can be an exciting area to study 
in the future.  
Currently, there are four main approaches to develop and extend the application of niosomes 
in the pharmaceutical field. The first approach aims to enhance the efficiency of targeted drug 
delivery by decorating niosomes with ligands. Encapsulation of drug in nano-vesicles is not 
enough for the successful delivery of drugs to areas such as the central nervous system; specific 
targeting is required to elevate the specific uptake and permeability of drugs across the blood-
brain-barrier. The second approach focuses on developing and optimizing novel techniques 
that improve the quality of niosomes and provide the possibility for scale-up in industrial 
production. Most niosomes are prepared by traditional methods, such as thin film rehydration, 
reverse phase evaporation, and ether injection method. These methods require the removal of 
organic solvents and they are expensive and time-consuming. To overcome these problems, 
Khan et al. developed a simple probe sonication method, which is an eco-friendly green 
technique with no addition of organic solvents (163). Besides, it is a low-cost and straight 
forward technique. In this method, only aqueous phase of the drug is mixed with surfactant, 
cholesterol and other surface additives, and subjected to ultra-sonication with a probe. 
Niosomes prepared by this technique were smaller with higher monodispersity and faster drug 
release as compared to niosomes prepared by traditional methods. By the third approach, new 
generations of niosomes for drug delivery and development of cosmeceutical products in 
practice have been continuously discovered and introduced with numerous outstanding features: 
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better stability, deformability, elasticity, enhanced skin permeation, the newer generation of 
niosomes including proniosomes, aspasomes, elastic niosomes and cationic niosomes. 
Proniosomes exhibits excellent stability owing to its potential to surmount physical instability 
including aggregation or fusion, leaking of entrapped drugs and sedimentation. They provide 
an additional convenience of transportation, distribution, storage and dosing. However, most 
of publications were focused on the utilization of proniosomes in transdermal drug delivery. 
Application of proniosomes can be further explored in areas such as aerosol drug delivery due 
to their unique properties. Elastic niosomes formed with the addition of edge activators such 
as sodium cholate and ethanol, they are superior to conventional niosomes for transdermal 
delivery due to its flexibility and deformability of being able to squeeze itself through pores on 
the skin which are much smaller than its diameter. The fourth approach involves the 
development of hybrid systems consists of niosomes and vehicles such as gel matrices. The 
hybrid system not only aims to improve drug release profile but also to obtain an adequate 
formulation with better patient acceptability. These four approaches of development will 
continuously be developed to adapt to the higher advancement of the pharmaceutical industry; 
more advanced niosomes will continuously be introduced in order to achieve targeted and site-
specific drug delivery.  
 
10. Conclusion  
In recent years, niosomes have been extensively studied for various applications, from topical, 
transdermal, oral to brain-targeted drug delivery. They are easy to prepare at a low cost as well 
as being able to achieve higher EE than their analog system, liposomes. This versatile drug 
delivery system has great potential in the fields of pharmaceutical and cosmetic sciences. 
Niosomes are promising delivery systems, their potential can be further enhanced by novel 
preparation, modification methods and novel formulation components, which allow them to 
achieve targeted delivery, better drug entrapment efficiency and develop vesicles with special 
structures. 
 
The authors did not receive any specific grant from funding agencies in the public, commercial, 
or not-for-profit sectors for preparation of this manuscript. 
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Tables 
Table 1. Advantages and disadvantages of niosome preparation methods. 
Preparation method Advantages Disadvantages References 
Thin film hydration 
(hand shaking) 
method 
An easy technique for 
laboratory researches 
Involves the use of 
organic solvents 
(3,67,68) 
Ether injection 
method 
An easy technique for 
laboratory researches 
Cannot be used for heat 
labile drugs 
(3,46) 
Reverse phase 
evaporation method 
High drug EE Involves the use of 
organic solvents 
(69) 
Trans-membrane pH 
gradient drug uptake 
process 
High drug EE Involves the use of 
organic solvents 
(70) 
Emulsion method An easy technique for 
laboratory research 
Involves the use of 
organic solvents 
(2) 
Lipid injection 
method 
No organic solvents 
involved 
Cannot be used for heat 
labile drugs 
(2) 
Niosome prepared 
using micelle solution 
and enzymes 
No organic solvents 
involved 
The active ingredient 
may be degraded by 
enzymatic degradation 
(1) 
Bubble method No organic solvents 
involved 
Cannot be used for heat 
labile drugs 
(71) 
Micro fluidization No organic solvents 
involved 
Cannot be used for heat 
labile drugs 
(2) 
Formation of 
niosomes from 
proniosomes 
No organic solvents 
involved 
Better physical stability 
Complex process 
Complete drug 
entrapment may not be 
(2,20,21) 
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possible during 
hydration 
Supercritical reverse 
phase evaporation 
method 
No organic solvents 
involved 
 
Special equipment 
required for this method 
(72) 
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Table 2. Characterization techniques for niosomes. 
Parameters Applied techniques or methods Reference 
Particle size and 
distribution 
Dynamic light scattering, Scanning electron 
microscopy (for solid samples), Transmission 
electronic microscopy (for liquid samples) 
(3) 
Morphology Transmission electronic microscopy, Negative-
staining transmission electronic microscopy, 
Freeze-fracture transmission electronic microscopy, 
Atomic force microscopy, Scanning electron 
microscopy, Cryo-scanning electron microscopy 
(2,23,76) 
Zeta potential Laser doppler anemometry (45,77,78) 
Bilayer 
characterization 
Fluorescence polarization (60) 
Vesicle stability Dynamic light scattering, microscopic techniques (20,49,55,67,79) 
EE UV-spectrometer, High performance liquid 
chromatography and Fluorescence 
(80-82) 
In vitro release Dialysis, Franz diffusion cells (22,25,34,76,78,83-
85) 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Examples of niosomes that have been investigated for oral drug delivery. 
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Drug  Surfactant Method of Preparation Reference 
Celecoxib Span 60 Proniosome derived niosome 
method 
(15) 
Diacerein Sorbitan monolaurate and 
poloxamer 184 
Thin film hydration (57) 
Ganciclovir Span 40 and 60 Reverse phase evaporation (95) 
Methotrexate Tween 80 Thin film hydration (48) 
Paclitaxel Span 40 Thin film hydration (91) 
Plasmid DNA 
for Hepatitis B 
Span 60 Reverse phase evaporation (69) 
Tetanus toxoid Span 60 and ween 20 Reverse phase evaporation (96) 
Tramadol  Tween 80, Tween 40, 
Span 80 and 40 
Proniosome derived niosome 
method 
(94) 
Valsartan Span 60 Proniosome derived niosome 
method 
(92) 
 
 
 
 
 
 
 
 
 
 
Table 4. Examples of niosomes that have been investigated for dermal and transdermal delivery. 
Drug  Surfactant Method of Preparation Referenc
e 
Acetazolamide Span 60 Thin film hydration (76) 
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Antioxidant enzyme 
catalase 
Sugar ester surfactants Thin film hydration (118) 
Artemisone Span 60 Thin film hydration  (83) 
Capsaicin Span 60 Thin film hydration (62) 
Diacerein Span 60 Thin film hydration (53) 
Diclofenac 
diethylammonium 
Tween 61 and Span 60 Thin film hydration (23) 
Ellagic acid Span 60 and Tween 60 Reverse phase evaporation (109) 
Ellagic acid Span 60 and Tween 60 Reverse phase evaporation (120) 
Enoxacin Span 40 and Span 60 A combination of ethanol 
injection and freeze drying 
(58) 
Estradiol Span 40, 60 and 85 Proniosome derived 
niosome method 
 
(105) 
Febuxostat Tween 20 and Span 60 Thin film hydration  (106) 
Finasteride Brij 52, 72, 97 and 
Span 40 
Thin film hydration (116) 
Gallidermin Tween 61 Freeze dried (40) 
Hydroxychloroquine Pluronic 27, Brij 98, 
Tween 20, 40, 65 and 
80, Span 20, 40, 60 and 
80 
Reverse phase evaporation (73) 
Itraconazole Span 40 and Span 60 Thin film hydration (114) 
Lacidipine Span 60 Thin film hydration (74) 
Methotrexate Span 60 Thin film hydration (98) 
Minoxidil Brij 52,76 and Span 20, 
40, 60 and 80 
Thin film hydration (35) 
Moxifloxacin Span 20 and 60, Tween 
20, 40, 60 and 80 
Thin film hydration  (119) 
N-terminal Tat-GFP 
fusion protein 
Tween 61 Freeze dried liposome 
method 
(99) 
Papain Tween 61 Thin film hydration (122) 
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Plasmid DNA 
(Hepatitis B) 
Span 85 Reverse phase evaporation (117) 
Propolis Span 60 Ethanol injection method (49) 
Resveratrol Span 80 Thin film hydration and 
ether injection 
(75) 
Resveratrol Gelot 64 Thin film hydration and 
ethanol injection 
(97) 
Risperidone Tween 20, 60 and 80, 
Span 20, 40, 60, 80 
Proniosome derived 
niosome method 
 
(110) 
Roxithromycin  Span 60 Thin film hydration (22) 
Salidroside Span 40 Thin film hydration (104) 
Sulfadiazine sodium Pluronic L64 and P105 Modified lipid film method (85) 
Sumatriptan 
succinate 
Brij 72, Eumulgin B2, 
Span 60 and 80 
Thin film hydration (45) 
Tenoxicam Span 80 and 60, Tween 
20 and 60 
Proniosome derived 
niosome method 
(coacervation phase 
separation) 
(112) 
Tramadol Span 20, 40, 60 and 80, 
Tween 20, 40, 60 and 
80 
Proniosome derived niosome 
method (coacervation phase 
separation) 
(100) 
Tretinoin Brij 30, Span 40 and 60 Thin film hydration (79) 
Tretinoin Pluol Oleique CC Thin film hydration (115) 
Tretinoin Alkyl polyglucoside Thin film hydration (101) 
Ursolic acid Span 60 Thin film hydration (50) 
Vitamin E Tween 80 and Span 20 Emulsion evaporation (102) 
8-methoxypsoralen Span 40 and 60 Thin film hydration (55) 
Sulfasalazine, 
propranolol, tyrosol 
Pluronic L64, sodium 
bis(2-ethylhexyl) 
sulfosuccinate) 
Thin film hydration (108) 
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Table 5. Examples of niosomes that have been investigated for ocular delivery. 
Drug Surfactant Method of Preparation Reference 
Gatifloxacin Span 60 Solvent injection method (77) 
Naltrexone Span 60 Reverse phase evaporation (122) 
Plasmid pCMS-
EGFP 
Tween 80 Emulsification and thin film 
hydration 
(13) 
Plasmid pCMS-
EGFP 
DOTMA and Tween 
60 
Reverse phase evaporation (56) 
Plasmid pCMS-
EGFP 
Tween 80 Solvent emulsification 
evaporation 
(123) 
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Tacrolimus Poloxamer 188 and 
lecithin 
Proniosome derived niosome 
method 
(11) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Examples of niosomes that have been investigated for pulmonary delivery. 
Drug Surfactant Method of Preparation Reference 
Amphotericin B Tween 80 - (124) 
Beclomethasone 
dipropionate 
Span 60 Thin film hydration and 
Proniosome derived 
niosome method 
(18) 
Ciprofloxacin Span 60 and Tween 
60 
Thin film hydration (126) 
Glucocorticoid Tween 20 Thin film hydration (125) 
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Table 7. Examples of niosomes that have been investigated for parenteral delivery.                                     
Drug Surfactant Method of Preparation Reference 
Acyclovir Span 20, 40, 60 and 
80 
Thin film hydration (127) 
Autoclaved 
Leishmania Major 
Span 20, 40, 60 80 
and Tween 20, 40, 
60, 80 
Thin film hydration (129) 
Cisplatin Span 40 Emulsion method (132) 
5-fluorouracil pH-sensitive 
niosomes 
Thin film hydration-probe 
ultrasound method 
(131) 
Gentamycin Span and Tween 
surfactants 
Thin film hydration (66) 
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Hydroxycamptothecin Span 60 Thin film hydration (130) 
Nystatin Span 40 and 60 Thin film hydration (128) 
Rifampicin Span surfactants Thin film hydration (80) 
Tamoxifen Span 40, 60, 80 and 
Tween 20 
Thin film hydration (43) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Examples of niosomes that have been investigated for transmucosal delivery.                                     
Drug Surfactant Method of Preparation Target delivery 
site  
Reference 
Benzocaine Span 80 and 
Span 85 
Reverse phase 
evaporation method 
Buccal mucosa (133) 
Influenza 
antigens 
 Dehydration-rehydration 
method 
Nasal mucosa (135) 
Metformin Span 80 Reverse phase 
evaporation method 
Vaginal mucosa (28) 
Risperidone Span 60 Ethanol injection method Nasal mucosa (134) 
Tenofovir Span 20, 40 
and 60 
Proniosome derived 
niosome method 
Vaginal mucosa (138) 
Tetanus 
toxoid 
Span 60 and 
Tween 20 
Reverse phase 
evaporation method 
Oral mucosa (96) 
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Table 9. Commercial cosmetic products containing niosomes. 
Product Name Marketed by Functions 
Niosome Plus Lancôme®  
(Clinchy, France) 
Foundation, clear and 
balance skin tone 
Niosome Plus perfected age 
treatment 
Lancôme® 
(Clinchy, France) 
Anti-wrinkle 
Mayu Niosome Base Cream Laon Cosmetics® 
(Seoul, Korea) 
Whitening and hydrating 
Anti-Age Response Cream Nouvelle-HAS cosmetics® 
(Varese, Italy) 
Anti-wrinkle 
Identik Masque Floral 
Repaire 
Identik® 
(Paris, France) 
Hair repair masque 
Indentik Shampooing Floral 
Repair 
Identik® 
(Paris, France) 
Hair repair shampoo 
Eusu Niosome Makam Pom 
Whitening Facial Cream 
Eusu® 
(Bangkok, Thailand) 
Whitening 
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Anne Möller Anti-Fatigue 
Eye Contour Roll-On 
Anne Möller® 
(Barcelona, Spain) 
Anti-puffiness and 
moisturizing 
 
 
 
 
 
 
 
 
 
Table 10. Examples of niosomes that have been investigated for bioactive delivery. 
Natural product Surfactant Method of Preparation Reference 
Curcumin Span 60, 80 and Tween 
20 
Proniosome derived niosome 
method 
(156) 
Ginkgo biloba extract Span 80 and Tween 80 Thin film hydration (151) 
Rice bran extract Tween 61 Thin film hydration  (72) 
Silymarin Span 60 and 40 Thin film hydration (154) 
Rutin Span 60 Thin film hydration (153) 
Resveratrol Span 60 and Span 80 Thin film hydration (7) 
Embelin Span 60 Thin film hydration (155) 
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Figure Captions 
Figure 1. The different types of surfactants. 
Figure 2. The most used surfactants. 
Figure 3. Chemical structure of cholesterol. 
Figure 4. Schematic structure of a single-chain surfactant, v is the hydrophobic group volume, 
lc is the hydrophobic group length, and a0 is the area of the hydrophilic head group. 
Figure 5. (a) Small unilamellar (SUV) (10 to 100 nm), (b) large unilamellar (LUV) (0.1 to 1 
µm) and (c) multilamellar vesicles (MLV) (0.5 µm to 10 µm). 
Figure 6. Schematic representation of the different types of surfactant based vesicular delivery 
systems. (a) Niosomes (b) elastic niosomes and (c) transfersomes. 
Figure 7. Schematic diagram of the preparation of niosomes using thin film hydration (hand 
shaking) method. 
Figure 8. Schematic diagram of the preparation of niosomes via ether injection method. 
Figure 9. Schematic diagram of the preparation of niosomes via the reverse phase evaporation 
method. 
Figure 10. Schematic diagram of the preparation of niosomes via the trans-membrane pH 
gradient drug uptake process. 
Figure 11. Schematic diagram of the preparation of niosomes using the emulsion method. 
Figure 12. Schematic diagram of the preparation of niosomes via lipid injection method. 
Figure 13. Schematic diagram of the preparation of niosomes using micellar solution and 
enzymes. 
Figure 14. Schematic diagram of the preparation of niosomes via the bubble method. 
Figure 15. Schematic diagram of the preparation of niosomes using the microfludization 
method. 
Figure 16. Schematic diagram of the preparation of proniosomes via coacervation phase 
separation method. 
Figure 17. Possible mechanisms of action of niosomes for dermal and transdermal drug 
delivery, (A) drug molecules released by a niosome; (B) adsorption of niosome and fusion with 
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SC; (C) intact niosome/elastic penetration through intact SC; (D) components of niosomes act 
as penetration enhancer to enhance drug absorption; (E) niosome penetration through hair 
follicles or pilosebaceous units (not to scale) (modified from El Maghraby et al., 2006 (103). 
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Figure 1. The different types of surfactants. 
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Figure 2. The most used surfactants.  
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Figure 3. Chemical structure of cholesterol. 
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Figure 4. Schematic structure of a single-chain surfactant, v is the hydrophobic group volume, 
lc is the hydrophobic group length, and a0 is the area of the hydrophilic head group. 
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Figure 5. (a) Small unilamellar (SUV) (10 to 100 nm), (b) large unilamellar (LUV) (0.1 to 1 
µm) and (c) multilamellar vesicles (MLV) (0.5 µm to 10 µm). 
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Figure 6. Schematic representation of the different types of surfactant based vesicular delivery 
systems. (a) Niosomes (b) elastic niosomes and (c) transfersomes. 
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Figure 7. Schematic diagram of the preparation of niosomes using thin film hydration (hand 
shaking) method. 
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Figure 8. Schematic diagram of the preparation of niosomes via ether injection method. 
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Figure 9. Schematic diagram of the preparation of niosomes via the reverse phase evaporation 
method. 
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Figure 10. Schematic diagram of the preparation of niosomes via the trans-membrane pH 
gradient drug uptake process. 
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Figure 11. Schematic diagram of the preparation of niosomes using the emulsion method. 
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Figure 12. Schematic diagram of the preparation of niosomes via lipid injection method. 
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Figure 13. Schematic diagram of the preparation of niosomes using micellar solution and 
enzymes. 
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Figure 14. Schematic diagram of the preparation of niosomes via the bubble method. 
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Figure 15. Schematic diagram of the preparation of niosomes using the microfludization 
method. 
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Figure 16. Schematic diagram of the preparation of proniosomes via coacervation phase 
separation method. 
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Figure 17. Possible mechanisms of action of niosomes for dermal and transdermal drug 
delivery, (A) drug molecules released by a niosome; (B) adsorption of niosome and fusion with 
the SC; (C) intact niosome/elastic penetration through intact SC; (D) components of niosomes 
act as penetration enhancer to enhance drug absorption; (E) niosome penetration through hair 
follicles or pilosebaceous units (not to scale) (modified from El Maghraby et al., 2006 (103). 
 
 
 
 

